London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...
Mary Kennedy and GSK Ireland launch Respiratory Syncytial Virus (RSV) awareness campaign encouraging over 65s and at-risk ...
Malay Mail on MSN7d
GSK’s Arexvy vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in MalaysiaGlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory ...
Dublin Live on MSN7d
Symptoms and signs of RSV as those over 65 and young children at riskIgnoring symptoms can lead to pneumonia and in some cases even hospitalisation for those particularly vulnerable ...
25, 2024 /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ) has been approved in Malaysia for RSV, a common respiratory virus that can lead ...
25, 2024 /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ) has been approved in Malaysia for RSV, a common respiratory virus that can lead to ...
Additionally, Parry points out uncertainties in GlaxoSmithKline’s RSV strategy, with vaccine efficacy data and booster approval processes posing challenges for the forecasted sales. His report ...
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common ...
Moreover, the analyst underscores challenges in GlaxoSmithKline’s respiratory and vaccine products. For instance, the RSV vaccine Arexvy faced a tough start to the 2024 season due to lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback